Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (January 2023)
19 slides from Clearpoint Neuro's investor presentation, Jan 11, 2023
Slide 1: ClearPoint Neuro – When your path is unclear, we point the way
CLEARPOINT NEURO WHEN YOUR PATH IS t WE POINT THE WAY. Nasdaq: CLPT January 2023
Slide 2: Forward-looking statements
© 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, prelimina
Slide 3: A neuro navigation and device company and biologics delivery enabler
© 2 0 2 3 C L E A R P O I N T N E U R O 3 A Neuro Navigation and Device Company with; • A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation • An expanding global installed base of more than 65 centers A Biolog
Slide 4: Company at a glance
4 100+ $20.6m (A) $37.5m (A) Solana Beach, CA Key Products: Marked Platforms Capital Equipment Razor / Razorblade model with ~95% of revenue from single- use disposables and services 69% (A,C) ~5% ~95% Disposables and Services © 2 0 2 3 C L E A R P O I N T N E U R O Irvine, CA London, UK 75+ (B)
Slide 5: Primary challenge for minimally invasive procedures
© 2 0 2 3 C L E A R P O I N T N E U R O 5 PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible Video source: https://www.youtube.com/watch?v=PsL9B7
Slide 6: Leverage live MR imaging to decide, guide, treat and confirm
© 2 0 2 3 C L E A R P O I N T N E U R O 6 Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.
Slide 7: SmartFrame trajectory towers and operating room robotic system
© 2 0 2 3 C L E A R P O I N T N E U R O 7 SmartFrame XG Trajectory Tower with ClearPoint 2.1 Software SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software* ClearPoint plans to translate more than 10 years of experienc
Slide 8: ClearPoint Maestro Brain Model
© 2 0 2 3 C L E A R P O I N T N E U R O 8 1. Shape Constrained, triangular mesh model enables point- based correspondence across multiple subjects. 2. Fast and capable of peri-procedural imaging without CPU acceleration. 3. This model is the basis for future navigation tools, for both the MRI suite
Slide 9: Leading centers in the installed base
ucsan Francisca si 5 University of Wisconsin” ‘Stanford University _ University of Michigan i! J ” Lucile Packard Children’s Hospital - University of Minnesota * Children’s Mercy Hospital a d _ Benioff Children’s Hospital Cleveland Clinic * 4 CHOA Scottish Rite jukhus Lund (Lund, San Francisco VA "-
Slide 10: Platform runs on all major scanners with 50+ partners
10 LASER THERAPY VISUALASE CLPT PLATFORM RUNS ON ALL MAJOR SCANNERS © 2 0 2 3 C L E A R P O I N T N E U R O IMPLANT NEURO STIMULATION LEADS … More than 50 total commercial and academic partners DELIVER BIOLOGICS AND DRUGS
Slide 11: Revenue by category, 2014–2023
11© 2 0 2 3 C L E A R P O I N T N E U R O $ M ill io n s $7.4 $11.2 $12.8 $7.4 $5.7$4.6 $3.6 $16.3 $25 $27 $20.6 $2.6 $3.4 $4.0 $5.2 $5.4 $7.1 $6.3 $8.1 $9.1 $0.9 $1.1 $1.0 $1.4 $0.8 $1.7 $1.5 $1.4 $2.3 $0.6 $1.2 $0.8 $0.6 $1.1 $2.4 $5.0 $6.8 $9.1 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Bi
Slide 12: Target indications and potential addressable market
Parkinson’s Disease 1,000,0001 60,0001 • $270 M - $1.35 B Drug Resistant Epilepsy 1,000,0002 11,0003 • $49.5 M - $198 M Refractory Essential Tremor 3,500,0004 60,0005 $180 M - $1.08 B Brain Tumors (n=3)6 35,0007,8 13,3007,8 $33.3 M - $300 M Severe Obsessive-Compulsive Disorder 500,0009,10 10,0009,10
Slide 13: Market sizing references
© 2 0 2 3 C L E A R P O I N T N E U R O 13 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 November 4). Neurona Therapeutic
Slide 14: Product development pipeline
© 2 0 2 3 C L E A R P O I N T N E U R O 14 First Use in 2022 Expected First Clinical Use by 2025* Fu n ct io n al N av ig at io n & T h e ra p y B io lo gi cs & D ru g D e liv e ry , A cc e ss T e ch n o lo gi e s ClearPoint Neuro Navigation Software v. 2.1 ClearPoint Maestro™ Brain Model ClearPoint
Slide 15: Training and remote support facility
© 2 0 2 3 C L E A R P O I N T N E U R O 15 • Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback • Showcase new technologies to Pharmaceutical and BCI partners • Home for Clinical Specialists to support cases remotely without trav
Slide 16: 4 pillar growth strategy by 2025
NEW THERAPY DEVICES NEURO NAVIGATION FOR DBS & BCI BIOLOGICS & DRUG DELIVERY 20252022 4 Pillar Growth Strategy by 2025 Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of $12B+ Enter the Neuro Laser Therapy Market Launch Maestro Brain Model a
Slide 17: Investment highlights
© 2 0 2 3 C L E A R P O I N T N E U R O 17 Unique platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Large, growing installed base in 65+ of 500+ leading Neurosurgery and research centers worldwide Expandable Platform wi
Slide 18: asda NER! combouite Nasdaqi00
rN asda NER! 9 combouite Nasdaqi00 “1.57% comp + 0.20% 10.29% 4 cnn SME2E van are REM se aeae ney tlteatas = P cisco COMCAST Soeend matchgroup @ © 2023 CLEARPOINT NEURO = SORTA ee
Slide 19: ClearPoint Neuro
CLEARPOINT NEURO
ClearPoint Neuro — Investor Presentation (January 2023) on 6ix